AURX
Price
$1.58
Change
-$0.12 (-7.06%)
Updated
Jun 6 closing price
Capitalization
79.6M
NCNA
Price
$0.05
Change
+$0.01 (+25.00%)
Updated
Jun 6 closing price
Capitalization
302.24K
Interact to see
Advertisement

AURX vs NCNA

Header iconAURX vs NCNA Comparison
Open Charts AURX vs NCNABanner chart's image
Nuo Therapeutics
Price$1.58
Change-$0.12 (-7.06%)
Volume$300
Capitalization79.6M
NuCana
Price$0.05
Change+$0.01 (+25.00%)
Volume$301.43M
Capitalization302.24K
AURX vs NCNA Comparison Chart
Loading...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AURX vs. NCNA commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AURX is a Hold and NCNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (AURX: $1.55 vs. NCNA: $0.04)
Brand notoriety: AURX and NCNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AURX: 1% vs. NCNA: 109%
Market capitalization -- AURX: $79.6M vs. NCNA: $302.24K
AURX [@Biotechnology] is valued at $79.6M. NCNA’s [@Biotechnology] market capitalization is $302.24K. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AURX’s FA Score shows that 0 FA rating(s) are green whileNCNA’s FA Score has 1 green FA rating(s).

  • AURX’s FA Score: 0 green, 5 red.
  • NCNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both AURX and NCNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NCNA’s TA Score shows that 5 TA indicator(s) are bullish.

  • NCNA’s TA Score: 5 bullish, 3 bearish.

Price Growth

AURX (@Biotechnology) experienced а +0.58% price change this week, while NCNA (@Biotechnology) price change was -7.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AURX($79.6M) has a higher market cap than NCNA($302K). AURX YTD gains are higher at: 10.643 vs. NCNA (-96.849). AURX has higher annual earnings (EBITDA): -2.39M vs. NCNA (-22.48M). NCNA has more cash in the bank: 6.75M vs. AURX (684K). AURX has less debt than NCNA: AURX (179K) vs NCNA (190K). AURX has higher revenues than NCNA: AURX (1.17M) vs NCNA (0).
AURXNCNAAURX / NCNA
Capitalization79.6M302K26,358%
EBITDA-2.39M-22.48M11%
Gain YTD10.643-96.849-11%
P/E RatioN/AN/A-
Revenue1.17M0-
Total Cash684K6.75M10%
Total Debt179K190K94%
FUNDAMENTALS RATINGS
AURX vs NCNA: Fundamental Ratings
AURX
NCNA
OUTLOOK RATING
1..100
2788
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
7
Undervalued
PROFIT vs RISK RATING
1..100
69100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
3799
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NCNA's Valuation (7) in the Biotechnology industry is significantly better than the same rating for AURX (95) in the null industry. This means that NCNA’s stock grew significantly faster than AURX’s over the last 12 months.

AURX's Profit vs Risk Rating (69) in the null industry is in the same range as NCNA (100) in the Biotechnology industry. This means that AURX’s stock grew similarly to NCNA’s over the last 12 months.

NCNA's SMR Rating (99) in the Biotechnology industry is in the same range as AURX (100) in the null industry. This means that NCNA’s stock grew similarly to AURX’s over the last 12 months.

AURX's Price Growth Rating (37) in the null industry is somewhat better than the same rating for NCNA (99) in the Biotechnology industry. This means that AURX’s stock grew somewhat faster than NCNA’s over the last 12 months.

AURX's P/E Growth Rating (100) in the null industry is in the same range as NCNA (100) in the Biotechnology industry. This means that AURX’s stock grew similarly to NCNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NCNA
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bullish Trend 12 days ago
83%
Momentum
ODDS (%)
Bullish Trend 12 days ago
78%
MACD
ODDS (%)
Bullish Trend 12 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
90%
Advances
ODDS (%)
Bullish Trend 25 days ago
79%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 12 days ago
89%
Aroon
ODDS (%)
Bearish Trend 12 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

AURX and

Correlation & Price change

A.I.dvisor tells us that AURX and ALZN have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AURX and ALZN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AURX
1D Price
Change %
AURX100%
N/A
ALZN - AURX
27%
Poorly correlated
-3.77%
VRAX - AURX
27%
Poorly correlated
-7.24%
YECO - AURX
26%
Poorly correlated
N/A
QSI - AURX
23%
Poorly correlated
-7.29%
NCNA - AURX
23%
Poorly correlated
-3.85%
More